Neurones Shares Rise 2.6% After Encouraging Quarterly Report

Organic Growth of 5.6% in the First Quarter

Neurones unveiled its first quarter 2026 revenues on Thursday, reporting an organic growth of 5.6%. This pace is slightly faster than the 5.1% growth reported for the entire 2025 fiscal year. The group also recorded a 5.8% increase in revenue in a previous quarter, although the operating margin had contracted. This Thursday's release marks the first reading of the year and has driven the stock up during the session. The next financial milestone on the calendar is the general meeting scheduled for June 4, 2026, followed by the second quarter revenue expected on August 5, 2026.

Stock Moves Above the 50-Day Average

At €37.75, the price is now well above the 50-day moving average (€35.50), which has been on the rise for several sessions. The 200-day average, at €39.65, remains out of immediate reach and reflects the downward pressure that has weighed on the stock over the past year, during which the value has dropped 21.92%. The RSI at 55 indicates a moderately bullish momentum, without excess. The price approaches the resistance identified at €38.20 and flirts with the upper boundary of the Bollinger Bands at €38.30, placing the stock at the high end of its short-term volatility channel. The negative beta of -0.23 confirms the stock's defensive nature against the CAC 40. The next significant figures will come from the second quarter revenue, on August 5.